加藤 昌志 Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. ICR.Cg-Tg(Mt1-RET)242Ina ICR.Cg-Tg(Mt1-RET)242Ina Cancer Research true 名古屋大学大学院医学系研究科・加藤昌志。(BALB/c x C57BL/6) X BALB/cへトランスジーンのインジェクションにより作出。ICR混合背景。 RBRC06250 メタロチオネインプロモーター制御下でがん遺伝子RETを発現するトランスジェニックマウス。皮膚黒色症モデル。腫瘍は発症しない。RET Tgホモは致死。, Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> <a href='https://brc.riken.jp/mus/pcr06250'>Genotyping protocol -PCR-</a> 条件を付加する。利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。<br>営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 Mt1-Ret 242 transgenic mice. The mice express the human RET under the control of the mouse MT1 promoter/enhancer. Mt1-RET homozygous mutant mice are embryonic lethal. Masashi KATO メタロチオネインプロモーター制御下でがん遺伝子RETを発現するトランスジェニックマウス。皮膚黒色症モデル。腫瘍は発症しない。RET Tgホモは致死。 B (1-3 months) Mus musclus Metallothionein-I promoter-enhancer, Homo sapiens RFP/RET cDNA, SV40 splicing signal-polyadenylation site, vector sequence Carrier x Noncarrier [or Crossing to Slc:ICR] Carrier x Noncarrier [or Crossing to Slc:ICR] Developed by Masashi Kato, Nagoya University Graduate School of Medicine. The Mt1-RET transgene was injected into the fertilized eggs of (BALB/c x C57BL/6) x BALB/c mice. ICR mixed background. ICR-RET#242, ICR-Mt1-RET Tg#242 ICR-RET#242, ICR-Mt1-RET Tg#242 B(1〜3か月)